develop COVID-19 diagnostic tests

Change Agents

08/06/2020 17:10

** Shares of drug developer  AVCO.O  rise ~8% to $1.79
    ** AVCO partners with GensKey Medical Technology to
co-develop and sell COVID-19 diagnostic tests  urn:newsml:reuters.com:*:nGNX91vh8M
    ** The companies will co-develop an antibody-based IgG/IgM
test and a polymerase chain reaction based diagnostic test to
detect the SARS-CoV-2 virus causing the COVID-19 disease 
    ** Both tests are already CE certified and await U.S. FDA
emergency use authorization - AVCO
    ** More than 510k shares traded till now, 2.47x its 25-DMA
    ** Stock down 7.2% YTD

 (Reporting by Trisha Roy in Bengaluru)
 ((Trisha.Roy@thomsonreuters.com; within U.S. +1 646 223 8780,
outside U.S. +91 80 6182 3635;))